Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22331155 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| SCHEMBL22331154 | 1.00 | PTGS1 (0.46) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| Hydrochloric Acid SCHEMBL22331153 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| Hydrochloric Acid SCHEMBL8378787 | 0.98 | PTGS1 (0.44) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| SCHEMBL20477516 | 0.88 | MEN1 (0.42) | PTGS1SLC7A11TSHR | |
| SCHEMBL27140359 | 0.87 | PTGS1 (0.43) | PTGS1SLC7A11ENPEPACHE | |
| SCHEMBL6891065 | 0.84 | PTGS1 (0.48) | PTGS1SLC7A11ENPEPANPEP | |
| SCHEMBL3487110 | 0.83 | ANPEP (0.36) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| SCHEMBL3487112 | 0.83 | ANPEP (0.36) | PTGS1SLC7A11TSHRSLC7A5ENPEP | |
| SCHEMBL107697 | 0.82 | PTGS1 (0.46) | PTGS1SLC7A11ENPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495088-A | Method and composition for permanent shaping of hair | PROCTER & GAMBLE (US) | 2009-07-29 | — | — | CN | claimed |
| WO-2008012732-A2 | METHOD AND COMPOSITION FOR PERMANENTLY SHAPING HAIR | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-31 | — | — | WO | claimed |
| US-20080025938-A1 | Method and composition for permanently shaping hair | PROCTER & GAMBLE COMPANY, THE | 2008-01-31 | — | — | US | claimed |
| EP-1880708-A1 | Method and composition for permanently shaping hair | Wella Aktiengesellschaft (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-0726251-B1 | Agents for permanent hair waving as well as hair keratin reducing cycsteine esters | WELLA AG (DE) | 1999-03-31 | — | — | EP | claimed |
| US-5679332-A | UNIFORM SHAPING OF HAIR WITHOUT CAUSING ALLERGIC SKIN REACTIONS OR LEAVING COATING ON HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | claimed |
| EP-0726251-A1 | Agents for permanent hair waving as well as hair keratin reducing cycsteine esters | Wella Aktiengesellschaft (DE) | 1996-08-14 | — | — | EP | claimed |
| CN-107513103-B | MASP isoforms as inhibitors of complement activation | OMEROS CORP. (US) | 2026-05-26 | — | — | CN | disclosed |
| CN-114502574-B | Use of variants of clostridial neurotoxins for the treatment of neurological disorders | 益普生生物制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119968211-A | Clostridium neurotoxin for treating bladder pain syndrome | 益普生生物制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119874853-A | Use of variants of clostridial neurotoxins for the treatment of neurological disorders | 益普生生物制药有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119698479-A | Retroviral vectors | IP2IPO创新有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119136826-A | Treatment of limb cramps | 益普生生物制药有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-0841894-A1 | PERMANENT PROCESS AND AGENT | Wella Aktiengesellschaft (DE) | 1998-05-20 | — | — | EP | disclosed |
| US-5679332-A | UNIFORM SHAPING OF HAIR WITHOUT CAUSING ALLERGIC SKIN REACTIONS OR LEAVING COATING ON HAIR | WELLA AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| WO-1997032563-A1 | PERMANENT PROCESS AND AGENT | WELLA AKTIENGESELLSCHAFT (DE) | 1997-09-12 | — | — | WO | disclosed |
| EP-0726251-A1 | Agents for permanent hair waving as well as hair keratin reducing cycsteine esters | Wella Aktiengesellschaft (DE) | 1996-08-14 | — | — | EP | disclosed |
| EP-0299715-A2 | Process for preparing L-tryptophan | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-01-18 | — | — | EP | disclosed |
| US-4487780-A | SUBSTITUTED CYSTEINE COMPOUNDS | SCHEINBERG ISRAEL H | 1984-12-11 | — | — | US | disclosed |
| US-4315028-A | COPPER OR GOLD COMPLEX OF PENICILLAMINE | SCHEINBERG ISRAEL H | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080025938-A1 | Method and composition for permanently shaping hair | KRT18, HHAT, AADAT | PTGS1 352/4885SLC7A11 192/4885TSHR 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.